

Selected Protocols for the Treatment of Hematologic Malignancies

Treatment Group	ID Number	Phase	Study Name	Principal Investigator
Lymphoma	08-063	Pilot	A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma	Eric Jacobsen, MD 617-632-6633
Lymphoma	06-275	I	A Phase I Trial of Vaccination with Lethally Irradiated Lymphoma Cells Admixed with GMCSF Secreting K562 Cells for the Treatment of Follicular Lymphoma	Eric Jacobsen, MD 617-632-6633
Lymphoma	08-066	II	Phase II study of Bortezomid/Lenalidomide in Relapsed/Refractory Mantle Cell*	Ann S. LaCasce, MD 617-632-5959
Lymphoma	08-019	IA/II	A Phase IA/II, Multicenter, Open-Label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Patients with Advanced Non-Hodgkin's or Hodgkin's Lymphoma who have Progressed after at Least Two Prior Therapies*	Arnold Freedman, MD 617-632-3441
Lymphoma	07-100	I	A Phase I Study of Obatoclox Mesylate (GX15-070MS) in Combination with Fludarabine and Rituximab in Previously Treated Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)	Jennifer Brown, MD, PhD 617-632-6692
Lymphoma	07-097	I	A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination with Fludarabine-Rituximab for Previously Untreated CLL/SLL*	Jennifer Brown, MD, PhD 617-632-6692
Lymphoma	07-360	II	Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients with Diffuse Large B-Cell Lymphoma following Autologous Stem Cell Transplantation*	Philippe Armand, MD 617-632-2305
Multiple Myeloma	08-031	I	An Open-Label Phase I Study of the Safety and Efficacy of GCS-100 alone and in combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma	Robert Schlossman, MD 617-632-5126
Multiple Myeloma	07-395	I/II	A Phase I/II Multicenter, Randomized, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of CC-4047 Alone and in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma who have received Prior Treatment that includes Lenalidomide and Bortezomib*	Paul Richardson, MD 617-632-2104
Multiple Myeloma	07-271	I/II	A Phase I Study of SGN-40 (anti-huCD40 mAb), Lenalidomide (Revlimid, cc-5013), and Dexamethasone in Patients with Multiple Myeloma	Nikhil Munshi, MD 617-632-5607
Multiple Myeloma	07-254	I	A Phase I Study of Enzastaurin plus Bortezomib Therapy in the Treatment of Relapsed or Refractory Multiple Myeloma	Irene M. Ghobrial, MD 617-632-4198
Multiple Myeloma	07-313	I	A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral LBH589 and IV Bortezomib in Patients with Multiple Myeloma	Kenneth Anderson, MD 617-632-2144
Multiple Myeloma	08-042	III	A Phase III Randomized, Open-label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse*	Paul Richardson, MD 617-632-2104

Treatment Group	ID Number	Phase	Study Name	Principal Investigator
Transplant	06-065	I/II	Phase I/II Trial of Bortezomib (Velcade) in Addition to Tacrolimus and Methotrexate to Prevent Graft- Versus-Host Disease after Mismatched Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplant	John Koreth, MBBS, D. Phil 617-632-2949
Transplant	06-196	I/II	Reduced Intensity Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia Followed by Vaccination with Lethally Irradiated Autologous Tumor Cells Admixed with Granulocyte Macrophage-Colony Stimulating Factor Secreting K562 cells	Catherine Wu, MD 617-632-5943
Transplant	08-100	II	Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin's Disease	Philippe Armand, MD, PhD 617-632-2305
Transplant	08-191	I	Phase II Trial of Bortezomib (Velcade) plus Prednisone for Initial Therapy of Chronic Graft-Versus-Host Disease	John Koreth, MBBS, D. Phil 617-632-2949
Transplant	08-160	I	Vaccination with Lethally Irradiated Autologous Myeloblasts Admixed with GM-CSF Secreting K562 cells (GM-K562) in Patients with Advanced MDS or AML After Allogeneic Hematopoietic Stem Cell Transplant	Vincent Ho, MD 617-632-5938
Transplant	08-274	I	A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Ex-Vivo 16, 16 Dimethyl-Prostaglandin E2 Expanded Umbilical Cord Blood Units*	Corey Cutler, MD, MPH, FRCP(C) 617-632-5946
Leukemia – ALL	06-254	II	DF/BWCC ALL Adult Consortium Trial: Adult ALL Trial*	Daniel DeAngelo, MD, PhD 617-632-2645
Leukemia – ALL	07-177	I/II	A Phase I/II Study of Cordycepin Plus Pentostatin in Patients with Refractory TDT-Positive Leukemia*	Daniel DeAngelo, MD, PhD 617-632-2645
Leukemia – AML	08-112	III	A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients <60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia*	Richard M. Stone, MD 617-632-2214
Leukemia – AML	08-065	II	A Multicenter, Open-Labeled, 2-Stage, Phase II Study of a Single-Agent Obatoclax Mesylate Administered for 3 Consecutive Days Every 2 Weeks to Older Patients with Previously Untreated Acute Myeloid Leukemia	Daniel DeAngelo, MD, PhD 617-632-2645
Leukemia – AML	08-051	II	A Phase II Open-Label, Multicenter Clinical Study of the Safety and Efficacy of SNS 595 Injection in Patients 60 Years of Age with Previously Untreated Acute Myeloid Leukemia*	Richard M. Stone, MD 617-632-2214
Leukemia – CML	05-308	II	A Phase II Study of Molecular Responses to Imatinib at Standard Doses for Previously Untreated Patients with Chronic Myelogenous Leukemia in Chronic Phase (CALGB 10303, S0325)*	Martha Wadleigh, MD 617-632-6685
Leukemia – Mastocytosis	04-307	II	A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients with Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL) +/- Hematological Clonal Non-Mast Cell Lineage Disease	Daniel DeAngelo, MD, PhD 617-632-2645

Dana-Farber/Brigham and Women's Cancer Center and Massachusetts General Hospital Cancer Center collaborate on clinical trials, education, and quality of care improvement. Clinical trials are conducted through the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.

If you are interested or would like more information about the clinical trials listed, please contact the principal investigator. For a broader listing of treatment protocols, visit our website at www.dfbwcc.org/clinicaltrials.